News


Articles


Events


News

March 2020
Grifols reinforces its commitment to all stakeholders as a response to the COVID-19 outbreak

The company takes several measures to keep responding to its stakeholders' needs in a responsible manner: society, employees, donors, patients, suppliers, shareholders and investors. Read more

February 2020
Grifols ranks in the Top 10 most sustainable companies in the Biotech sector

'The Sustainability Yearbook 2020' has recently been published by S&P Global in collaboration with Robeco SAM. This annual publication reflects the results of SAM's 2019 Corporate Sustainability Assessment, the world's leading methodology for the evaluation of companies in social, environmental and good corporate governance matters. More than 4,700 institutions from various sectors worldwide participated in this edition.

Grifols has taken ninth place in the SAM Environmental, Social, and Governance (ESG) 2020 ranking of the Biotech sector, entering the world's top 10 most sustainable companies in the industry, led by Biogen and AbbVIE.

Grifols is also part of the 31 Spanish companies recognized as leaders in sustainability worldwide. Within this group Acciona, Banco Santander, Enagás, Ferrovial, Inditex, Meliá and Naturgy were awarded gold medals.

September 2018
Grifols has been included in the FTSE4Good Index

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company that enhances the health and well-being of patients through the development of plasma-derived medicines, clinical diagnostic solutions and specialty pharmaceuticals for hospital use, has been included in sustainability stock index FTSE4Good.

The sustainability indices consider environmental, social and governance (ESG) criteria in addition to financial indicators.

Specifically, Grifols has been chosen to form part of the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex indices.

The FTSE4Good Index independently rates companies on their environmental, social and corporate governance (ESG) performance. The FTSE4Good indices are used by a broad range of financial market agents in their investment decisions.

The benchmarks for inclusion in FTSE4Good are based on an extensive market consultation process that encompasses numerous stakeholder groups, including government entities, consultants, academics, investment experts, the business community and NGOs.

May 2018
New line Form Fill Seal in Grifols facilities in Parets del Vallès

Grifols Partnership is highly committed to the pharmaceutical industry, and continues to grow and invest in order to maintain its competitiveness within the market. Our engagement with clients and the high quality of our sterile solutions is our number one priority. Proof of our dedication to innovation is the installation of the first form-fill-seal (FFS) line at the manufacturing site in Parets del Vallès, Spain. It is the fourth FFS line in Grifols, after the three FFS lines in Murcia, Spain.

The new line will be divided in two stages: the first one will consist of a dosing and double bagging automated process and the second will be a fully automated line, including formation, filling, dosing and sealing (double bag). The addition of the FFS line will provide additional manufacturing capacity and flexibility to meet the specifications of our customers in terms of multi format (from 50 ml to 1000 ml) and connectors (twist-off, needle free and Fleboflex® connector). The investment in sterile manufacturing technology was approximately 2M €.

The first stage of the new line will be operational in the first half of 2019.

March 2018
Five minutes with Marga Viñes, Business Development Manager – Contract Manufacturing, Grifols – DCAT Week'18

During the Dcat Week'18 in New York, our Business Development Manager was interviewed by the Teknoscienze publisher. A five-minute conversation where Marga Viñes talks about Grifols, our capabilities in contract manufacturing and the recent investments we have made. This proved to be a different and rewarding way to show our expertise and experience. Read more

May 2017
Grifols Normal saline solution produced in its Murcia facility receives U.S. FDA approval

The FDA approval allows Grifols to market its normal saline solution in 500-millimeter polypropylene bags in the U.S. hospital sector and guarantees the Group's self-sufficiency. The product is manufactured in Grifols' production plant in Las Torres de Cotillas (Murcia).

Grifols U.S. network of plasma-donation centers will also use the IV solution as a preventative measure to restore the circulatory volume of donors.

As Grifols continues to drive the internationalization of its Hospital Division, this approval opens up new possibilities for future authorizations to sell other products manufactured in its facilities located in Parets del Vallès (Barcelona) and Las Torres de Cotillas (Murcia). It also confirms the company's strategy to promote the complementarity of its products and services among business divisions.

March 2016
Grifols invests in Sterile Manufacturing

Grifols is a Spanish healthcare company with headquarters in Barcelona, which specializes in plasma-derived proteins and contract manufacturing of sterile solutions. The company has recently made investments in sterile manufacturing technology with the installation of a fourth form-fill-seal (FFS) line at its manufacturing site in Murcia, Spain. The addition of the new FFS line will increase the company's flexible bag manufacturing capacity by 30%. The new line can operate using the standard Grifols connector and can also manufacture bags with one or two tubes.

The new line will be operational in 2017 once validation has been completed and approved by Spanish health authorities. Grifols is also waiting for US Food and Drug Administration approval for the new FFS line as part of the company's plan to expand sales of parenteral solutions in new markets. The Murcia facility has also been fitted with a new high-capacity autoclave and a new conditioning line to handle the increase in production.

Another production line is scheduled to be completed in the company's facility in Parets del Vallés, Barcelona, during the first half of 2018.

Articles

Grifols Partnership, Parenterals CDMO. Rare specialist for tomorrow's medicines

Chemistry Today: January/February 2020

Growth in the pharmaceutical industry is no longer exclusively driven by large pharmaceutical companies. The switch in the marketplace from a focus on blockbuster drugs to an emphasis on therapies that treat orphan and rare diseases has led to the rise of small and emerging pharma companies founded to advance novel medicines for specialized patient populations. These innovators require the support of contract service providers that recognize their unique requirements.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

The Critical Role of Continuous Improvement in Parenteral Drug Manufacturing

Pharma's Almanac: January 2020

In the competitive pharmaceutical manufacturing landscape, the ability to continuously achieve improvements in efficiency and productivity is essential to success. Given the higher complexity of parenteral drug manufacturing, continuously improving production processes is also paramount for ensuring the highest level of quality.
Read full article

Antonio A. Gómez. Head of Pharmaceutical Production Division, Laboratorios Grifols

Customer Engagement and Information Sharing are Essential for success in Orphan Drug Outsourcing

Pharma's Almanac: August 2019

Developing cost‐effective manufacturing solutions for smaller volumes of highly specialized orphan drugs can be challenging, particularly for small and emerging pharmaceutical companies seeking to bring novel rare disease treatments to market. A contract service provider with experience in specialized technologies and accelerated development programs that is also committed to customer engagement, information sharing and the formation of real partnerships can be the key to achieving success.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Supporting small and emerging pharma through collaboration and specialized expertise

Pharma's Almanac: May 2019

Growth in the pharmaceutical industry is no longer exclusively driven by large pharmaceutical companies. The switch in the marketplace from a focus on blockbuster drugs to an emphasis on therapies that treat orphan and rare diseases has led to the rise of small and emerging pharma companies founded to advance novel medicines for specialized patient populations. These innovators require the support of contract service providers that recognize their unique requirements.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Catering to a Growing Demand for Small-Volume Parenteral Manufacturing

Pharma's Almanac: April 2019

Drug candidates are becoming increasingly complex as manufacturers continue to focus on niche and personalized medicines. Contract development and manufacturing organizations with process and capacity flexibility, and wide-ranging expertise in small-volume GMP manufacturing are needed to support efforts by pharma companies to rapidly bring these specialized products to the market.
Read full article

Oriol Prat. Director Contract Manufacturing, Grifols

Grifols, a reliable and trusted partner in the injectable field

Chemistry Today (Pharma Horizon): March 2019

As an expert parenteral CDMO, Grifols Partnership is aware that the high cost of manufacturing injectable drugs, as well as quality issues and compliance requirements, forces companies to outsource these products. For an increasing number of companies, seeking technically and operationally superior contract-service partners to deliver capacity and resources is becoming a key component of their patient-centric strategy and the fastest path to market.
Read full article

Marga Viñes. Business Development Manager, Grifols International

Investing in Form-Fill-Seal Technology

Pharma's Almanac: February 2019

Extensive process understanding is required to ensure the consistent manufacture of high-quality sterile parenteral products. At Grifols, our use of state-of-the-art automated aseptic processing systems, including form-fill-seal (FFS) technology, ensures control with minimal human intervention.
Read full article

Lluc Mercadé. Manufacturing Director, Laboratorios Grifols

Continuous Quality is Essential in Parenteral Manufacturing

Pharma's Almanac: December 2018

Ensuring quality is the first concern of any pharmaceutical company in the development, manufacture and control of drug products. The highest level of quality is essential for achieving optimal patient safety, especially in the manufacture of parenteral drugs. The use of a quality-by-design approach and compliance with requirements for parametric release are two key components of a successful and effective quality program.
Read full article

Marta Serra. Technical Director, Laboratorios Grifols

Terminal Sterilization For Parenteral Drugs: Finding The Right CDMO Partner

Pharma's Almanac: September 2018

Parenteral products must undergo some form of sterilization, and terminal sterilization is generally the preferred method. Because sterile products manufacturing requires specialized expertise, many pharmaceutical companies rely on contract service providers. Choosing a CDMO with demonstrated success developing and commercializing robust terminal sterilization processes is essential to ensure patient safety.
Read full article

Lluis Twose. Managing Director, Laboratorios Grifols

A Risk Analysis Approach to Producing Environmentally Sensitive Parenterals

Pharma's Almanac: June 2018

The manufacture of sterile parenteral products is a complex and challenging process. When APIs used in formulation are sensitive to oxygen, moisture or light, issues in manufacturing are multiplied. Using risk analysis and a quality-by-design (QbD) approach across all aspects of the manufacturing process can ensure the consistent production of even the most sensitive high-quality parenteral drug products.
Read full article

Estela Llorens. Research and Development Director, Laboratorios Grifols
Oriol Riera. Head of Pharmaceutical Development, Laboratorios Grifols

Panel Discussion on Parenteral Drug Manufacturing

Pharma Horizon: April 2018

Grifols Partnership has had the pleasure to participate in the second Pharma Horizon panel discussion for 2018. The topic this time was the Parenteral Drug Manufacturing Process and our Business Development Manager, Marga Viñes, has taken part giving her point of view on parenteral drug manufacturing challenges. We must always bear in mind that behind each parenteral product there is a patient.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Expanding US Supply Options for Large-Volume Parenterals

Pharma's Almanac: March 2018

Grifols has implemented its vertical integration philosophy to ensure the consistent supply of high-quality Sodium Chloride 0.9% solution to its blood/plasma donor centers. Despite the growing interest in LVPs, only a few manufacturers produce these important products for the US market.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Mitigating Shortages of Injectable Drugs in the United States

Pharma's Almanac: September 2017

The majority of short supply drugs are sterile injectable products due to manufacturing issues, particularly quality problems. It is an important objective to mitigate some shortages because they can delay or deny patients the crucial treatments they require.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Small Molecule Injectable Manufacturing: Challenges and Complexities

Pharma's Almanac: June 2017

There is no doubt about the importance of medicines based on small molecules, especially for parenteral formulations, but are we aware of the complexity that a successful production of complex products such as sterile injectables requires? The answer is that injectable products must be manufactured to very high quality and sterility standards.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Facilitating Tech Transfer For Parenteral Products

Pharma's Almanac: March 2017

The ability to track & trace pharmaceutical product in the distribution channel has always been a regulatory imperative, but those regulations are evolving and becoming more sophisticated to improve drug safety and the threat of counterfeits in the supply chain.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Advancing Patient-Centric Parenteral Drug Strategies

Pharma's Almanac: December 2016

Parenterally administered drug will remain the delivery option of choice, especially in the era of biologics, but their ultimate success therapeutically and commercially hinges on how well these drugs can be integrated into a patient-centric continuum of care.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership
Oriol Prat. Director Contract Manufacturing, Grifols Partnership

Track & Trace Systems for Serialization and Aggregation

Pharma's Almanac: September 2016

Pharmaceutical outsourcing by definition requires the transfer of technology from sponsor company to the service provider. Outsourcing of sterile injectable fill-finish projects brings additional complexities and risk.
Read full article

Pere Villanova. Technological Innovation Manager, Grifols

A Holistic Interpretation of commitment to Quality

Pharma's Almanac: April 2016

Parental Manufacturing Market Trends.
Read full article

Oriol Prat. Director Contract Manufacturing, Grifols Partnership

Parental Outsourcing Trends

Contract Pharma: March 2016

Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parental dosage development and manufacturing market.
Read full article

Tim Wright. Editor Contract Pharma

Patient Safety and Parental Delivery Systems

Pharma's Almanac February 2016

Parental Drug Delivery.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Parenteral Manufacturing Market Trends

Contract Pharma: March 2015

Switching from concentrated formulas to premixed solutions that are ready to use for injection.
Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Sterile Solutions: How to Choose the Right CDMO?

Pharaceutical Technology Europe: March 2015

How do you know if you have chosen the right CDMO?
Do you just wait to have the answer when your product is out on the market? 

Read full article

Marga Viñes. Business Development Manager, Grifols Partnership

Events

The Grifols Partnership team will attend the following events. Interested in meeting us there? Please send us an email with your area of interest and contact details to partnership@grifols.com

March 23-26, 2020. New York City, USA
DCAT WEEK 2020

Meet us at our suite #507 at the InterContinental Barclay Hotel. Please email us for an appointment at partnership@grifols.com

DCAT Week is the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries. We look forward to seeing you there!

Grifols is a DCAT member

May 5-7, 2020. Pennsylvania Convention Center, Philadelphia, USA
CPHI North America 2020

We look forward to seeing you at our stand #1142. Please email us for an appointment at partnership@grifols.com

CPhI North America is the only event in the region that hosts the full pharma supply chain. With 7 dedicated zones in 1 massive expo hall, this event is the perfect way to connect with potential new suppliers and find new solutions for your business. Come visit us!

June 8-11, 2020. San Diego Convention Center San Diego, USA
BIO International Convention

Find us at our booth #4017. Please email us for an appointment at partnership@grifols.com

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.

Come visit us!

Booth#: 4017

September 24-25, 2020. New Brunswick, United States

Please email us for an appointment at partnership@grifols.com

The two-day conference and one-day exhibition on September 22nd provide the perfect venue for easy, informal discussions for manufacturing, packaging, laboratory services and more. We look forward to seeing you there!

October 13-15, 2020. Fiera Milano, Rho, Italy

As part of the CPhI global event, ICSE connects the pharmaceutical community with outsourcing solution providers. We look forward to seeing you there!

Booth#: 4G110